Wayne Pisano - 01 Jun 2026 Form 4 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Jun 2026, 16:30:46 UTC
Prior SEC filing
01 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kirk Look, Attorney-in-Fact

Key filing fact

Wayne Pisano filed Form 4 for ONCOLYTICS BIOTECH INC (ONCY) on 03 Jun 2026.

Key facts

  • This page summarizes Wayne Pisano's Form 4 filing for ONCOLYTICS BIOTECH INC (ONCY).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Jun 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 01 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001743611 Primary reporting owner

Pisano Wayne

Relationship
Director
Address
C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO
Signature
/s/ Kirk Look, Attorney-in-Fact
Signature date
03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONCY transaction Derivative

Stock Option

Award

Transaction value
Shares
+30,000
Change %
Price
$0.000000*
Shares after
30,000
Date
01 Jun 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$1.06
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

Footnote F2

The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .